Oral antibiotic therapy for the treatment of infective endocarditis: A systematic review

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Al Omari, Awad ^a   Cameron, D W ^b,c,d   Lee, Craig ^b,d   Corrales Medina, Vicente F ^b,c,d,e  

^a SECURITY FORCES HOSPITAL   (Saudi Arabia)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e NONE   (Canada)

Author keywords

Endocarditis; Oral antibiotic therapy; Outcomes; Treatment

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; CHLORTETRACYCLINE; CIPROFLOXACIN; CLOXACILLIN; ERYTHROMYCIN; FLUCLOXACILLIN; GENTAMICIN; LINEZOLID; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN V; PROBENECID; PROPICILLIN; RIFAMPICIN; STREPTOMYCIN; SULFADIAZINE; SULFANILAMIDE; SULFAPYRIDINE; SULFATHIAZOLE; SULFONAMIDE; VANCOMYCIN; DICLOXACILLIN; PHENETICILLIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; CLINICAL EVALUATION; DOSE RESPONSE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ABUSE; OUTCOME ASSESSMENT; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS BOVIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; ANTIBIOTIC SENSITIVITY; DRUG EFFICACY; DRUG SAFETY; ENTEROCOCCUS; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); STREPTOCOCCUS EQUINUS;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; ENDOCARDITIS, BACTERIAL; HUMANS;

EID: 84899105032     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-140     Document Type: Article

References (51)

1. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med 2001, 345(18):1318-1330. 10.1056/NEJMra010082, 11794152.
2. Que YA, Moreillon P. Infective endocarditis. Nat Rev Cardiol 2011, 8(6):322-336. 10.1038/nrcardio.2011.43, 21487430.
3. Wilson WR, Gilbert DN, Bisno AL, Freedman LR, Smith C, Drusano G, Kaye D. Evaluation of new anti-infective drugs for the treatment of infective endocarditis. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992, 15 Suppl 1:S89-95.
4. Cunha BA. Oral antibiotic therapy of serious systemic infections. Med Clin North Am 2006, 90(6):1197-1222. 10.1016/j.mcna.2006.07.009, 17116444.
5. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA, Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005, 111(23):e394-434. 10.1161/CIRCULATIONAHA.105.165564, 15956145, Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease.
6. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151(4):264-269. W264, 10.7326/0003-4819-151-4-200908180-00135, 19622511.
7. How to read clinical journals: III. To learn the clinical course and prognosis of disease. Can Med Assoc J 1981, 124(7):869-872. 1705372, 7214286.
8. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001, 357(9263):1191-1194. 10.1016/S0140-6736(00)04337-3, 11323066.
9. Colli A, Campodonico R, Gherli T. Early switch from vancomycin to oral linezolid for treatment of gram-positive heart valve endocarditis. Ann Thorac Surg 2007, 84(1):87-91. 10.1016/j.athoracsur.2007.02.096, 17588391.
10. Dworkin RJ, Lee BL, Sande MA, Chambers HF. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet 1989, 2(8671):1071-1073.
11. Chetty S, Mitha AS. High-dose oral amoxycillin in the treatment of infective endocarditis. S Afr Med J 1988, 73(12):709-710.
12. Pinchas A, Lessing J, Siegman-Igra Y, Liron M. Oral treatment of bacterial endocarditis. Isr J Med Sci 1983, 19(7):646-648.
13. Phillips B, Watson GH. Oral treatment of subacute bacterial endocarditis in children. Arch Dis Child 1977, 52(3):235-237. 10.1136/adc.52.3.235, 1546282, 849003.
14. Gray IR, Tai AR, Wallace JG, Calder JH. Oral treatment of bacterial endocarditis with penicillins. Lancet 1964, 2(7351):110-114.
15. Campeau L, Lefebvre M. Oral treatment of malignant streptococcal endocarditis by potassium phenethicillin: 10 cases. Union Med Can 1963, 92:873-880.
16. Friedberg CK. Treatment of subacute bacterial endocarditis with aureomycin. J Am Med Assoc 1952, 148(2):98-103.
17. Schein J, Baehr G. Sulfonamide therapy of subacute bacterial endocarditis. Am J Med 1948, 4(1):66-72. 10.1016/0002-9343(48)90373-8, 18920944.
18. Heldman AW, Hartert TV, Ray SC, Daoud EG, Kowalski TE, Pompili VJ, Sisson SD, Tidmore WC, Vom Eigen KA, Goodman SN, Lietman PS, Petty BG, Flexner C. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996, 101(1):68-76. 10.1016/S0002-9343(96)00070-8, 8686718.
19. Stamboulian D, Bonvehi P, Arevalo C, Bologna R, Cassetti I, Scilingo V, Efron E. Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci. Rev Infect Dis 1991, 13(Suppl 2):S160-163.
20. Lafforgue G, Arellano C, Vachoux C, Woodley J, Philibert C, Dupouy V, Bousquet-Melou A, Gandia P, Houin G. Oral absorption of ampicillin: role of paracellular route vs. PepT1 transporter. Fundam Clin Pharmacol 2008, 22(2):189-201. 10.1111/j.1472-8206.2008.00572.x, 18353114.
21. Gordon C, Regamey C, Kirby WM. Comparative clinical pharmacology of amoxicillin and ampicillin administered orally. Antimicrob Agents Chemother 1972, 1(6):504-507. 10.1128/AAC.1.6.504, 444250, 4680813.
22. Sutherland R, Croydon EA, Rolinson GN. Amoxycillin: a new semi-synthetic penicillin. Br Med J 1972, 3(5817):13-16. 10.1136/bmj.3.5817.13, 1788503, 4402672.
23. Gray IR. The choice of antibiotic for treating infective endocarditis. Q J Med 1975, 44(175):449-458.
24. Moreno RA, Boldrina L, Guermani A, Mazucheli J, Sverdloff C, Borges NC. Comparative bioavailability study of two phenoxymethylpenicillin potassium tablet formulations in healthy volunteers. Int J Clin Pharmacol Ther 2007, 45(12):669-676. 10.5414/CPP45669, 18184536.
25. Watanakunakorn C. The use of beta-lactam antibiotics in the treatment of septicaemia and endocarditis. Scand J Infect Dis Suppl 1984, 42:110-116.
26. Sabath LD. Phenoxymethylpenicillin (penicillin V) and phenethicillin. Med Clin North Am 1970, 54(5):1101-1111.
27. Bolon MK. The newer fluoroquinolones. Infect Dis Clin North Am 2009, 23(4):1027-1051. x, 10.1016/j.idc.2009.06.003, 19909896.
28. Kaatz GW, Barriere SL, Schaberg DR, Fekety R. The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis. J Antimicrob Chemother 1987, 20(5):753-758. 10.1093/jac/20.5.753, 3429376.
29. Zak O, Scheld WM, Sande MA. Rifampin in experimental endocarditis due to Staphylococcus aureus in rabbits. Rev Infect Dis 1983, 5(Suppl 3):S481-490.
30. Hackbarth CJ, Chambers HF, Sande MA. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother 1986, 29(4):611-613. 10.1128/AAC.29.4.611, 180452, 3707110.
31. Kaatz GW, Seo SM, Barriere SL, Albrecht LM, Rybak MJ. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1989, 33(8):1184-1187. 10.1128/AAC.33.8.1184, 172621, 2802547.
32. Tebas P, Martinez Ruiz R, Roman F, Mendaza P, Rodriguez Diaz JC, Daza R, de Letona JM. Early resistance to rifampin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis. J Infect Dis 1991, 163(1):204-205.
33. Dajcs JJ, Thibodeaux BA, Marquart ME, Girgis DO, Traidej M, O'Callaghan RJ. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. Antimicrob Agents Chemother 2004, 48(6):1948-1952. 10.1128/AAC.48.6.1948-1952.2004, 415620, 15155183.
34. Lister PD. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clin Infect Dis 2001, 32(Suppl 1):S33-38.
35. Entenza JM, Vouillamoz J, Glauser MP, Moreillon P. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother 1997, 41(8):1662-1667. 163981, 9257737.
36. Galani L, Pefanis A, Sakka V, Iliopoulos D, Donta I, Triantafyllidi H, Skiadas I, Karayiannakos P, Giamarellou H. Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2009, 33(1):65-69. 10.1016/j.ijantimicag.2008.07.021, 18818055.
37. Berrington AW, Koerner RJ, Perry JD, Bain HH, Gould FK. Treatment of Staphylococcus aureus endocarditis using moxifloxacin. Int J Med Microbiol 2001, 291(3):237-239. 10.1078/1438-4221-00126, 11554565.
38. Foo SS, Lye DC. Methicillin-sensitive Staphylococcus aureus tricuspid valve endocarditis with annular abscess cured with oral levofloxacin and rifampicin. Int J Antimicrob Agents 2007, 30(3):275-277. 10.1016/j.ijantimicag.2007.04.008, 17644346.
39. Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 66 Suppl 4:iv7-iv15.
40. Hall B. The absorption and distribution of aureomycin in man; a review of the literature and study of the concentration of aureomycin in the serum, urine and cerebrospinal fluid after oral administration. Ann Intern Med 1954, 40(4):743-754.
41. Rolain JM, Boulos A, Mallet MN, Raoult D. Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis. Antimicrob Agents Chemother 2005, 49(7):2673-2676. 10.1128/AAC.49.7.2673-2676.2005, 1168648, 15980335.
42. Rolain JM, Mallet MN, Raoult D. Correlation between serum doxycycline concentrations and serologic evolution in patients with Coxiella burnetii endocarditis. J Infect Dis 2003, 188(9):1322-1325. 10.1086/379082, 14593588.
43. Cunha BA. Minocycline versus doxycycline for meticillin-resistant Staphylococcus aureus (MRSA): in vitro susceptibility versus in vivo effectiveness. Int J Antimicrob Agents 2010, 35(5):517-518. 10.1016/j.ijantimicag.2010.01.017, 20202796.
44. Nicolau DP, Freeman CD, Nightingale CH, Coe CJ, Quintiliani R. Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1994, 38(7):1515-1518. 10.1128/AAC.38.7.1515, 284585, 7979281.
45. Clumeck N, Marcelis L, Amiri-Lamraski MH, Gordts B. Treatment of severe staphylococcal infections with a rifampicin-minocycline association. J Antimicrob Chemother 1984, 13 Suppl C:17-22.
46. Lawlor MT, Sullivan MC, Levitz RE, Quintiliani R, Nightingale C. Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline. J Infect Dis 1990, 161(4):812-814. 10.1093/infdis/161.4.812, 2319175.
47. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992, 117(5):390-398. 10.7326/0003-4819-117-5-390, 1503330.
48. Ono T, Shiota S, Hirota K, Nemoto K, Tsuchiya T, Miyake Y. Susceptibilities of oral and nasal isolates of Streptococcus mitis and Streptococcus oralis to macrolides and PCR detection of resistance genes. Antimicrob Agents Chemother 2000, 44(4):1078-1080. 10.1128/AAC.44.4.1078-1080.2000, 89818, 10722517.
49. McKenna S, Evans G. Macrolides: A Canadian Infectious Disease Society position paper. Can J Infect Dis 2001, 12(4):218-231. 2094825, 18159344.
50. Prunier AL, Malbruny B, Tande D, Picard B, Leclercq R. Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. Antimicrob Agents Chemother 2002, 46(9):3054-3056. 10.1128/AAC.46.9.3054-3056.2002, 127407, 12183270.
51. Iversen K, Host N, Bruun NE, Elming H, Pump B, Christensen JJ, Gill S, Rosenvinge F, Wiggers H, Fuursted K, Holst-Hansen C, Korup E, Schønheyder HC, Hassager C, Høfsten D, Larsen JH, Moser C, Ihlemann N, Bundgaard H. Partial oral treatment of endocarditis. Am Heart J 2013, 165(2):116-122. 10.1016/j.ahj.2012.11.006, 23351813.